Jansson A - In refractory cases, drugs have to be applied which are not approved for this indication, especially in children. This paper reviews the published data of 48 paediatric patients suffering from severe SLE who underwent therapy with rituximab – a genetically engineered CD-20 antibody. The total observation period was up to 30 months. Responses seem promising with a good safety profile altogether. Successful repeated therapies have been reported. Published data seem to be inhomogeneous giving an evidence level of grade IV. Prospective studies and especially controlled trials are still needed.
See all
